Speaker Information

Check back for updates!


Dan Barouch, M.D., Ph.D.
William Bosworth Castle Professor of Medicine and Professor of Immunology, Harvard Medical School
Director of the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

Dr. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery.  His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies. His group has also applied their vaccine expertise to preclinical and clinical studies of other infectious diseases of global significance, including Zika virus, tuberculosis, and most recently SARS-CoV-2.

Larry Corey, M.D.
Past President and Director
Professor, Vaccine and Infectious Disease Division
Principal Investigator, HIV Vaccine Trials Network
Fred Hutchinson Cancer Research Center
Professor, Medicine and Laboratory Medicine
University of Washington

Dr. Corey is past president and director of the Fred Hutchinson Cancer Research Center and professor of its Vaccine and Infectious Disease Division. He is also a professor of Medicine and Laboratory Medicine at the University of Washington, was head of the UW Virology Division (1978-2010), and led the AIDS Clinical Trials Group (ACTG) (1987-1992). He has been PI of the HIV Vaccine Trials Network (HVTN) since its inception in 1999, and is an internationally renowned expert in virology, viral immunology and vaccine development.

As PI of the HVTN, Corey established an NIH-supported global network of scientists on five continents with over 70 clinical trial sites, 45 of which are in sub-Saharan Africa.

Corey received his BS and MD from the University of Michigan and his infectious diseases training at UW. He is a member of the National Academy of Medicine and the American Academy of Arts and Sciences, and the recipient of numerous awards. He is one of the most highly cited biomedical researchers in the last 20 years and is the author of over 800 scientific publications.

Mark Denison, M.D.
Edward Claiborne Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology and Immunology, and Director of the Division of Pediatric Infectious Diseases
Vanderbilt University Medical Center

Mark R. Denison, MD, is the Edward Claiborne Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, and Director of the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center. The Denison Lab has been NIH funded for investigation of coronavirus replication, pathogenesis, evolution, and countermeasures for over 30 years. Coronaviruses (CoVs) are a family of RNA viruses causing respiratory infections and also zoonotic infections of global importance as potential pandemic pathogens and agents of bioterrorism, including SARS-CoV, MERS-CoV, and the current SARS-CoV-2 (COVID-19) pandemic. The Denison lab has focused on antiviral development since 2013 and initiated and led preclinical testing for anti CoV antivirals remdesivir and EIDD-2801. The lab also has identified multiple novel targets for antivirals and virus attenuation including the polymerase and novel proofreading exonuclease. Dr. Denison is a Fellow of AAAS, the American Academy of Microbiology, and the Association of American Physicians. He has served on national and international forums and panels regarding development of policies for biosecurity and biosafety, including current membership on the National Science Advisory Board for Biosecurity (NSABB).

Disclosures: Dr. Denison has a financial relationship with Gilead and Moderna.

Anthony S. Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases (NIAID)
Chief, NIAID Laboratory of Immunoregulation
National Institutes of Health, Bethesda, Maryland

Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases.  Dr. Fauci has been a key advisor to six Presidents and their administrations on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. As an HIV/AIDS researcher he has been involved in the scientific effort since AIDS was recognized in 1981, conducting pivotal studies that underpin the current understanding of the disease and efforts to develop therapies and tools of prevention.  Dr. Fauci was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has helped save millions of lives throughout the developing world.

Dr. Fauci is the long-time chief of the NIAID Laboratory of Immunoregulation. He has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise mechanisms whereby immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener's granulomatosis), and lymphomatoid granulomatosis.

Dr. Fauci has made seminal contributions to the understanding of how HIV destroys the body's defenses leading to its susceptibility to deadly infections. Further, he has been instrumental in developing highly effective strategies for the therapy of patients living with HIV/AIDS, as well as for a vaccine to prevent HIV infection. He continues to devote much of his research time to identifying the nature of the immunopathogenic mechanisms of HIV infection and the scope of the body's immune responses to HIV.

Dr. Fauci is a member of the US National Academy of Sciences and the US National Academy of Medicine, and is the recipient of numerous prestigious awards for his scientific and global health accomplishments, including the National Medal of Science, the Robert Koch Medal, the Mary Woodard Lasker Award for Public Service, the Prince Mahidol Prize, The Gairdner Canada Award for Global Health, and the Presidential Medal of Freedom.  He has been awarded 45 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,300 scientific publications, including several major textbooks.

Tom Gallagher, Ph.D.
Professor of Microbiology and Immunology
Loyola University Chicago

Tom Gallagher is a Professor of Microbiology and Immunology at Loyola University Chicago. He has been at Loyola for most of his career and has been highly active in teaching, service and research. His research is in virology, with specific focus on coronaviruses and the mechanisms by which they enter host cells. He is thankful for the opportunity to speak to the ASGCT about SARS-CoV-2 entry and antiviral targets to treat COVID19. 

Michael Joyner, M.D.
Mayo Clinic​

The laboratory of Michael J. Joyner, M.D., is interested in how humans respond to various forms of physical and mental stress during activities such as exercise, hypoxia, standing up, and blood loss.

Dr. Joyner and his team study how the nervous system regulates blood pressure, heart rate and metabolism in response to these forms of stress. They are also interested in how blood flow to muscle and skin responds to these stressors. These responses are studied in young healthy subjects, healthy older subjects, and people with conditions such as heart failure.

Finally, Dr. Joyner is personally interested in the role of integrative approaches in science as a powerful tool to integrate and critique data from reductionist approaches.

Florian Krammer, Ph.D.
Professor of Vaccinology
Icahn School of Medicine at Mount Sinai

Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna (Austria) in 2010. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014 he became an independent principal investigator and is currently Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, Zika virus, hantaviruses, filoviruses and arenaviruses.

Disclosures: Dr. Krammer has a financial relationship with Mount Sinai Health System.

Paul McCray, M.D.
Professor of Pediatrics, Microbiology and Immunology, and Internal Medicine
University of Iowa

Dr. McCray is the Executive Vice Chair in the Department of Pediatrics, Associate Director of the Center for Gene Therapy of Cystic Fibrosis, and holds the Roy J. Carver Chair in Pulmonary Research at the University of Iowa. He is a member of the American Society for Clinical Investigation, the American Pediatric Society, the Association of American Physicians, the American Association for the Advancement of Science, and the American Academy of Microbiology. As a pediatric pulmonologist, Dr. McCray has long-standing interests in cystic fibrosis, host-pathogen interactions, airway epithelial biology, pulmonary innate immune responses, and the applications of gene transfer for lung diseases. One focus of his laboratory program has been to better understand the pathogenesis of cystic fibrosis as a path to new treatments. Another focus is the study of virulent coronavirus infections (SARS, MERS, COVID-19), their pathogenesis, the development of small animal models of disease, and paths to therapies.  Dr. McCray’s work is supported by NIH and the Cystic Fibrosis Foundation.

Disclosures: Dr. McCray has a financial relationship with Spirovant Scienes, Inc., and Oryn Therapeutics.

Linfa Wang, Ph.D.
Director of the Programme in Emerging Infectious Diseases
Duke-NUS Medical School, Singapore

Dr. Wang is an international leader in the field of emerging zoonotic viruses and virus-host interaction. He was a member of the WHO SARS Scientific Research Advisory Committee, and played a key role in identification of bats as the natural host of SARS-like viruses. He currently serves on multiple WHO and OIE committees and working groups on COVID-19. He has more than 400 publications, including papers in Nature, Science, and The Lancet, among others. He is the Editor-in-Chief for the open access Virology Journal. In 2010, Prof. Wang was elected to the Australian Academy of Technological Sciences and Engineering.

Susan Weiss, Ph.D.
Professor and Vice Chair, Department of Microbiology
Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens
Perelman School of Medicine, University of Pennsylvania

Susan obtained her Ph.D. in Microbiology from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco. She is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine at the University of Pennsylvania. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA.


ASGCT Policy Summit

September 23-25, 2020